Group D Streptococcus (GDS) Infections (Streptococcus bovis/Streptococcus gallolyticus)

Back

Background

Group D Streptococcus (GDS) infections in humans are most often associated with bacteremia, with or without endocarditis. Other less-common infections involving group D streptococci include urinary tract infections, meningitis, neonatal sepsis, spontaneous bacterial peritonitis, septic arthritis, and vertebral osteomyelitis. Traditionally, group D streptococcal infections have predominantly been caused by Streptococcus bovis, but recent taxonomy changes have produced confusion among clinicians.

S bovis is well-established in the literature as a cause of bacteremia and endocarditis and has a well-known association with gastrointestinal malignancy. For simplicity, S bovis is the terminology used throughout this article.

Pathophysiology

The portal of entry for S bovis bacteremia is the gastrointestinal tract. The urinary tract, hepatobiliary tree and the oropharynx can also be sources of infection in some cases. S bovis bacteremia, with or without endocarditis, is strongly associated with an underlying malignancy or premalignant lesions of the colon. S bovis has also been isolated more frequently from the stools of patients with such malignancies.

Associations with nonmalignant diseases of the colon have also been reported. A similar relationship between bacteremia (or endocarditis) and chronic liver disease has been established.[1] In rare cases, gastric cancer has been found upon investigation following S bovis bacteremia.[2] Every patient with S bovis bacteremia, with or without endocarditis, should undergo evaluation for gastrointestinal malignancy.

Epidemiology

Frequency

United States

Isolation of S bovis from microbiology specimens, particularly blood cultures, is uncommon. The SENTRY Antimicrobial Surveillance Program in the United States does not list group D streptococci among the 10 most common organisms that cause bloodstream infections, accounting for no more than 1% of all cases.[3] According to the SCOPE Program, streptococci accounted for 6% of all blood culture isolates among 30 US hospitals, with S bovis accounting for 2.4% of those streptococci.[4]

Despite these findings, the microorganisms most commonly implicated as etiologic agents in subacute infective endocarditis occurring on native valves in patients who were not intravenous drug users were Streptococcus viridans and S bovis. Since 1997, a review of the International Collaboration on Endocarditis merged database (ICE-MD) found that S bovis accounted for 16.7% of all streptococcal infective endocarditis cases reported in the United States.[5] However, this study reported findings from only two US hospitals.

International

SENTRY data indicate that S bovis was isolated in 1.3% and 6.9% of streptococcal bloodstream infections in Canada and Latin America, respectively. Kupferwasser et al compared patients with S bovis endocarditis with patients with endocarditis secondary to other causative microorganisms. In this German study, 177 cases of definite infective endocarditis were reported between 1983 and 1996, with 22 cases (12.5%) caused by S bovis.[6]

More-recent studies have shown an increasing proportion of infective endocarditis caused by S bovis, particularly in France and neighboring areas of southern Europe. An analysis of 559 cases of infective endocarditis in France in 1999 found that 25% were caused by S bovis.[7] A Spanish study recently reported similar findings.[8]

Mortality/Morbidity

Morbidity: A study by Kupferwasser et al showed that S bovis endocarditis is a severe infection. The duration of fever and the increased acute-phase reactants after the onset of treatment were longer than with infective endocarditis caused by other bacteria. Involvement of multiple valves and valvular damage resulting in moderate-to-severe regurgitation were also more common. Embolic events were less common and correlated with the smaller sizes of S bovis vegetations observed on transesophageal echocardiograms. Gastrointestinal lesions were observed in nearly 50% of patients with S bovis endocarditis.[6]

Mortality: Mortality rates from the same study were 45% for S bovis endocarditis and 25% for non– S bovis endocarditis. This is higher than the 7.5-38% mortality range reported previously. The increased mortality was related to the virulence of S bovis and to a more common occurrence of underlying extracardiac disease of which patients died during follow-up care.[6]

Race

Streptococcus group D infections have no known racial predilection.

Sex

Streptococcus group D infections have no reported sexual predilection.

Age

Nearly all individuals with S bovis endocarditis are older than 50 years, with a mean age of 67 years and age range of 49-76 years. This once meant that patients with S bovis endocarditis were on average older than patients with endocarditis caused by other species. However, the mean age for all cases of endocarditis has recently increased, making patients with S bovis endocarditis generally no older than those with endocarditis from other causes.[9]

History

Meningitis, peritonitis, septic arthritis, urinary tract infections, and neonatal sepsis due to group D streptococci have clinical features referable to the site of infection. When due to group D streptococcal infection, the clinical features do not differ from other bacterial causes of these infections.

The following are findings associated with group D streptococcal endocarditis:

The following are findings associated with group D streptococcal bacteremia:

Physical

Group D streptococcal bacteremia manifests as fever without localizing signs.

The following are the physical findings of group D streptococcal endocarditis:

Causes

Group D streptococci, along with other catalase-negative, gram-positive cocci, belong to the family Streptococcaceae. Group D streptococci may also be referenced as the S bovis–Streptococcus equinus complex.[10] S bovis has recently been reclassified as Streptococcus gallolyticus, but references to S bovis remain prevalent in the clinical literature. S equinus is almost never isolated from human specimens.

Group D streptococci share many features with enterococci. In the mid 1980s, Streptococcus faecalis, Streptococcus faecium, and others were reclassified under the newly created genus Enterococcus.

Similar to enterococci, S bovis possesses the group D lipoteichoic acid antigen in its cell wall. It also shares the ability to hydrolyze esculin in the presence of bile. Unlike enterococci, S bovis fails to grow in broth containing a concentration of 6.5% sodium chloride and is negative for the pyrrolidonyl arylamidase reaction.

S bovis was traditionally differentiated into two biotypes, termed S bovis or S bovis I (now termed S gallolyticus subspecies gallolyticus) and S bovis variant or S bovis II. S bovis II was further differentiated into 2 sub-biotypes, S bovis II/1 (now termed Streptococcus infantarius) and S bovis II/2 (now termed S gallolyticus subspecies pasteurianus or Streptococcus pasteurianus).

In a study of patients with S bovis bacteremia, Ruoff et al demonstrated the following:[11]

Laboratory Studies

Basic laboratory studies to evaluate for Streptococcus group D infections should include CBC count, electrolyte evaluation, creatinine level, and LFTs.

Blood cultures

Blood cultures are the most important tests.

Blood culture results are usually positive during the first 24-48 hours. In cases of endocarditis and sustained bacteremia, blood culture results are positive.

Gram stain from the blood culture bottles demonstrates gram-positive cocci in pairs or chains. S bovis cannot be differentiated from other streptococci using Gram staining.

Differentiating S bovis from Streptococcus salivarius is sometimes very difficult because S salivarius yields a positive reaction on the bile-esculin test. This happens with approximately 20% of the isolates.

Sensitivity testing is recommended, although most S bovis strains are exquisitely sensitive to penicillin. In a study by Mouton et al on 19 strains of S bovis, the minimal inhibitory concentrations (MICs) 50 and 90 were, respectively, 0.06 mg/L (susceptible) and 1 mg/L (intermediate susceptibility). The highest MIC was 2 mg/L (resistant).[12]

Imaging Studies

Echocardiography

Transthoracic or transesophageal (more sensitive) echocardiography frequently permits visualization of vegetations. Echocardiography should be performed in all patients with S bovis bacteremia.

An absence of vegetation does not rule out infective endocarditis. For more information on echocardiography findings, see Infective Endocarditis.

Colonoscopy

This test is used to detect malignant lesions of the colon.

Colonoscopy should be performed in all patients with S bovis bacteremia or endocarditis.

Regular-interval follow-up colonoscopy should be performed in patients in whom no lesion is found on initial investigation.

Esophagogastroduodenoscopy

Esophagogastroduodenoscopy (EGD) is used to detect malignant lesions of the esophagus, stomach, and duodenum.

EGD should be performed in patients with S bovis bacteremia or endocarditis who have no evidence of colonic malignancy.

Liver ultrasonography and CT scanning

Both of these studies should be performed in cases of associated hepatobiliary disease.

Usually, liver ultrasonography is performed first, followed by CT scanning.

Other Tests

Consider referral of the organism for formal MIC testing if the response to antibiotic therapy is unfavorable.

Medical Care

Most S bovis isolates are susceptible to penicillin (MIC ≤ 0.1 mg/L) and should be treated with intravenous penicillin G or ceftriaxone for 4 weeks. An alternative for only uncomplicated cases of native-valve endocarditis is a 2-week course of therapy with a combination of penicillin G or ceftriaxone and gentamicin. For moderately susceptible isolates (MIC >0.1 mg/L, MIC ≤ 0.5 mg/L), penicillin or ceftriaxone and gentamicin should be administered for 4 weeks and 2 weeks, respectively.[13]

Surgical Care

Surgical valve replacement is indicated in some cases, particularly for heart failure or complications of endocarditis (see Complications).

Mycotic aneurysm clipping after cerebral arteriography may be indicated.

Based on the findings from the evaluation of the gastrointestinal tract, colon or hepatobiliary surgery may be indicated.

Consultations

Consult an infectious diseases specialist to confirm the diagnosis of Streptococcus group D infection and to recommend treatment for endocarditis or bacteremia.

Consult a cardiologist to evaluate heart function, including echocardiography findings.

A cardiovascular surgeon can assist with valvular replacement, if indicated. Having the cardiac surgeon involved from the start is a good practice in case the patient's heart condition abruptly deteriorates.

Obtain a consultation with a neurosurgeon for possible clipping if mycotic aneurysms are present.

Obtain a consultation with a general surgeon or gastroenterologist to investigate and treat colonic or hepatobiliary disease.

Medication Summary

The goals of pharmacotherapy are to eradicate the infection, to reduce morbidity, and to prevent complications.

Penicillin G (Pfizerpen)

Clinical Context:  Interferes with synthesis of cell wall mucopeptide during active multiplication, resulting in bactericidal activity against susceptible microorganisms.

Ceftriaxone (Rocephin)

Clinical Context:  Alternative to penicillin. Third-generation cephalosporin equally effective against infections caused by S bovis. Has advantage of once daily administration. For penicillin IgE–mediated hypersensitivity, cross-reactions with third-generation cephalosporins are very rare.

Vancomycin (Lyphocin, Vancocin, Vancoled)

Clinical Context:  A glycopeptide very active against isolates of S bovis. Useful for patients who are allergic to penicillin.

Gentamicin (Garamycin, Gentacidin)

Clinical Context:  Should be used together with penicillin when bacterial isolates are only moderately susceptible to penicillin or to reduce treatment duration from 4 wk to 2 wk when infection is fully susceptible to penicillin. Preferred aminoglycoside for synergy. Should be administered at lower dosage (3 mg/kg/d) than for treatment of infections caused by gram-negative organisms (5 mg/kg/d).

Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.

Further Outpatient Care

Patients who are stable and infected with a penicillin-sensitive strain of S bovis and whose conditions have improved with antibiotic therapy can be discharged to complete their intravenous treatment on an outpatient basis.

Further Inpatient Care

Approximately 72 hours after beginning antibiotics, run two series of blood cultures. If the results are positive, repeat every 3-4 days until the results are negative.

Monitor serum creatinine levels closely in patients receiving gentamicin and vancomycin.

Complications

Complications of S bovis infection are similar to those of S viridans endocarditis.

S bovis subacute bacterial endocarditis can involve the heart, kidneys, CNS, spleen, lungs, and eyes. Mycotic aneurysms are potential complications. See the following:

Prognosis

See Mortality/Morbidity.

S bovis endocarditis is an aggressive disease with significant mortality.

Heart failure is a frequent complication and an indication for valve replacement.

In a study by Kupferwasser et al, 73% of patients with S bovis endocarditis underwent surgical treatment, but only 34%, 34%, and 41% of patients with endocarditis caused by other streptococci, staphylococci, or other bacteria underwent surgery, respectively.[6]

What are group D streptococcus (GDS) infections?What is the pathophysiology of group D streptococcus (GDS) infections?What is the prevalence of group D streptococcus (GDS) infections in the US?What is the global prevalence of group D streptococcus (GDS) infections?What is the morbidity associated with group D streptococcus (GDS) infections?What is the mortality associated with group D streptococcus (GDS) infections?What are the racial predilections of group D streptococcus (GDS) infections?What are the sexual predilections of group D streptococcus (GDS) infections?Which age groups have the highest prevalence of group D streptococcus (GDS) infections?Which medical conditions are associated with group D streptococcus (GDS) infections?What are the signs and symptoms of group D streptococcal endocarditis?What are the signs and symptoms of group D streptococcal bacteremia?Which physical findings are characteristic of group D streptococcal bacteremia?Which group D streptococci (GDS) infect humans?What are the differential diagnoses for Group D Streptococcus (GDS) Infections (Streptococcus bovis/Streptococcus gallolyticus)?Which lab tests are performed in the diagnosis of group D streptococcus (GDS) infections?What is the role of echocardiography in the evaluation of group D streptococcus (GDS) infections?What is the role of colonoscopy in the evaluation of group D streptococcus (GDS) infections?What is the role of esophagogastroduodenoscopy (EGD) in the evaluation of group D streptococcus (GDS) infections?What is the role of liver ultrasonography and CT scanning in the evaluation of group D streptococcus (GDS) infections?When is MIC testing indicated in the management of group D streptococcus (GDS) infections?How are group D streptococcus (GDS) infections treated?What is the role of surgery in the treatment of group D streptococcus (GDS) infections?Which specialist consultations are beneficial for patients with group D streptococcus (GDS) infections?What is the goal of drug treatment for group D streptococcus (GDS) infections?Which medications in the drug class Antibiotics are used in the treatment of Group D Streptococcus (GDS) Infections (Streptococcus bovis/Streptococcus gallolyticus)?What is included in long-term monitoring of patients with group D streptococcus (GDS) infections?What is included in the inpatient care of group D streptococcus (GDS) infections?What are possible complications of group D streptococcus (GDS) infections?What is the prognosis of group D streptococcus (GDS) infections?

Author

Shirin A Mazumder, MD, FIDSA, Associate Professor of Medicine, Director of Infectious Disease Fellowship Program, Division of Infectious Diseases, Department of Internal Medicine, University of Tennessee Health Science Center College of Medicine, University of Tennessee Methodist Physicians

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

John L Brusch, MD, FACP, Assistant Professor of Medicine, Harvard Medical School; Consulting Staff, Department of Medicine and Infectious Disease Service, Cambridge Health Alliance

Disclosure: Nothing to disclose.

Chief Editor

Michael Stuart Bronze, MD, David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London

Disclosure: Nothing to disclose.

Additional Contributors

Christian P Sinave, MD, Associate Professor, Department of Medical Microbiology and Infectious Diseases, University of Sherbrooke Faculty of Medicine, Canada

Disclosure: Nothing to disclose.

Pranatharthi Haran Chandrasekar, MBBS, MD, Professor, Chief of Infectious Disease, Department of Internal Medicine, Wayne State University School of Medicine

Disclosure: Nothing to disclose.

Tomas Michael Ferguson, MD, Consulting Staff, Department of Internal Medicine, Division of Infectious Diseases, Tripler Army Medical Center

Disclosure: Nothing to disclose.

Acknowledgements

John W Downs, MD Resident Physician, Department of Medicine, Tripler Army Medical Center

John W Downs, MD is a member of the following medical societies: Alpha Omega Alpha and American College of Physicians

Disclosure: Nothing to disclose.

References

  1. Tripodi MF, Adinolfi LE, Ragone E, et al. Streptococcus bovis endocarditis and its association with chronic liver disease: an underestimated risk factor. Clin Infect Dis. 2004 May 15. 38(10):1394-400. [View Abstract]
  2. Montalto M, Izzi D, La Regina M, Nucera G, Manna R, Gasbarrini G. Non-life-threatening sepsis: report of two cases. Am J Med Sci. 2004 May. 327(5):275-7. [View Abstract]
  3. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis. 2004 Sep. 50(1):59-69. [View Abstract]
  4. Pfaller MA, Jones RN, Marshall SA, et al. Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. The SCOPE Hospital Study Group. Diagn Microbiol Infect Dis. 1997 Dec. 29(4):259-63. [View Abstract]
  5. Hoen B, Chirouze C, Cabell CH, Selton-Suty C, Duchêne F, Olaison L, et al. Emergence of endocarditis due to group D streptococci: findings derived from the merged database of the International Collaboration on Endocarditis. Eur J Clin Microbiol Infect Dis. 2005 Jan. 24(1):12-6. [View Abstract]
  6. Kupferwasser I, Darius H, Muller AM, et al. Clinical and morphological characteristics in Streptococcus bovis endocarditis: a comparison with other causative microorganisms in 177 cases. Heart. 1998 Sep. 80(3):276-80. [View Abstract]
  7. Giannitsioti E, Chirouze C, Bouvet A, Béguinot I, Delahaye F, Mainardi JL, et al. Characteristics and regional variations of group D streptococcal endocarditis in France. Clin Microbiol Infect. 2007 Aug. 13(8):770-6. [View Abstract]
  8. Corredoira J, Alonso MP, Coira A, Casariego E, Arias C, Alonso D, et al. Characteristics of Streptococcus bovis endocarditis and its differences with Streptococcus viridans endocarditis. Eur J Clin Microbiol Infect Dis. 2008 Apr. 27(4):285-91. [View Abstract]
  9. Karchmer AW. Infective endocarditis. Libby P, Bonow RO, Mann DL, Zipes DP, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 8th ed. Saunders; 2007. 1713.
  10. van't Wout JW, Bijlmer HA. Bacteremia due to Streptococcus gallolyticus, or the perils of revised nomenclature in bacteriology. Clin Infect Dis. 2005 Apr 1. 40(7):1070-1. [View Abstract]
  11. Ruoff KL, Miller SI, Garner CV, et al. Bacteremia with Streptococcus bovis and Streptococcus salivarius: clinical correlates of more accurate identification of isolates. J Clin Microbiol. 1989 Feb. 27(2):305-8. [View Abstract]
  12. Mouton JW, Endtz HP, den Hollander JG, et al. In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis. J Antimicrob Chemother. 1997 May. 39 Suppl A:75-80. [View Abstract]
  13. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005 Jun 14. 111(23):e394-434. [View Abstract]
  14. Bayer AS, Scheld WM. Endocarditis and intravascular infections. Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Disease. 5th ed. Philadelphia, Pa: Churchill Livingstone; 2000. Vol 1: 857-902.
  15. Burns CA, McCaughey R, Lauter CB. The association of Streptococcus bovis fecal carriage and colon neoplasia: possible relationship with polyps and their premalignant potential. Am J Gastroenterol. 1985 Jan. 80(1):42-6. [View Abstract]
  16. Corredoira J, Alonso MP, Coira A, Varela J. Association between Streptococcus infantarius (formerly S. bovis II/1) bacteremia and noncolonic cancer. J Clin Microbiol. 2008 Apr. 46(4):1570. [View Abstract]
  17. Cunha BA. Antibiotic Essentials. 7th ed. Royal Oak, Mich: Physicians Press; 2008.
  18. Cunha BA. Antimicrobial therapy of multidrug-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci, and methicillin-resistant Staphylococcus aureus. Med Clin North Am. 2006 Nov. 90(6):1165-82. [View Abstract]
  19. Cunha BA. New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited. Med Clin North Am. 2006 Nov. 90(6):1089-107. [View Abstract]
  20. Cunha BA. Oral antibiotic therapy of serious systemic infections. Med Clin North Am. 2006 Nov. 90(6):1197-222. [View Abstract]
  21. Diekema DJ, Pfaller MA, Jones RN, et al. Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USA, Canada and Latin America. SENTRY Participants Group. Int J Antimicrob Agents. 2000 Feb. 13(4):257-71. [View Abstract]
  22. Diekema DJ, Pfaller MA, Jones RN; SENTRY Participants Group. Age-related trends in pathogen frequency and antimicrobial susceptibility of bloodstream isolates in North America: SENTRY Antimicrobial Surveillance Program, 1997-2000. Int J Antimicrob Agents. 2002 Dec. 20(6):412-8. [View Abstract]
  23. García-Porrúa C, González-Gay MA, Monterroso JR, Sánchez-Andrade A, González-Ramirez A. Septic arthritis due to Streptococcus bovis as presenting sign of 'silent' colon carcinoma. Rheumatology (Oxford). 2000 Mar. 39(3):338-9. [View Abstract]
  24. Gavin PJ, Thomson RB Jr, Horng SJ, Yogev R. Neonatal sepsis caused by Streptococcus bovis variant (biotype II/2): report of a case and review. J Clin Microbiol. 2003 Jul. 41(7):3433-5. [View Abstract]
  25. Gonzlez-Quintela A, Martinez-Rey C, Castroagudín JF, et al. Prevalence of liver disease in patients with Streptococcus bovis bacteraemia. J Infect. 2001 Feb. 42(2):116-9. [View Abstract]
  26. Grant RJ, Whitehead TR, Orr JE. Streptococcus bovis meningitis in an infant. J Clin Microbiol. 2000 Jan. 38(1):462-3. [View Abstract]
  27. Hechmann Wittrup I, Chenoufi Schaadt ML, Arpi M, Danneskiold-Samsoe B. Bacteremia complicated by vertebral osteomyelitis due to Streptococcus bovis. Eur J Clin Microbiol Infect Dis. 1999 May. 18(5):365-7. [View Abstract]
  28. Klein RS, Catalano MT, Edberg SC, et al. Streptococcus bovis septicemia and carcinoma of the colon. Ann Intern Med. 1979 Oct. 91(4):560-2. [View Abstract]
  29. Klein RS, Recco RA, Catalano MT, et al. Association of Streptococcus bovis with carcinoma of the colon. N Engl J Med. 1977 Oct 13. 297(15):800-2. [View Abstract]
  30. Moellering RC Jr. Enterococcus species, Streptococcus bovis, and Leuconostoc species. Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Disease. 6th ed. Philadelphia, Pa: Churchill Livingstone; 2005.
  31. Moellering RC Jr, Watson BK, Kunz LJ. Endocarditis due to group D streptococci. Comparison of disease caused by streptococcus bovis with that produced by the enterococci. Am J Med. 1974 Aug. 57(2):239-50. [View Abstract]
  32. Murray HW, Roberts RB. Streptococcus bovis bacteremia and underlying gastrointestinal disease. Arch Intern Med. 1978 Jul. 138(7):1097-9. [View Abstract]
  33. Pfaller MA, Jones RN, Doern GV, et al. Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Progr. Diagn Microbiol Infect Dis. 1999 Apr. 33(4):283-97. [View Abstract]
  34. Rehm SJ. Outpatient intravenous antibiotic therapy for endocarditis. Infect Dis Clin North Am. 1998 Dec. 12(4):879-901, vi. [View Abstract]
  35. Reynolds JG, Silva E, McCormack WM. Association of Streptococcus bovis bacteremia with bowel disease. J Clin Microbiol. 1983 Apr. 17(4):696-7. [View Abstract]
  36. Selton-Suty C, Hoen B, Grentzinger A, et al. Clinical and bacteriological characteristics of infective endocarditis in the elderly. Heart. 1997 Mar. 77(3):260-3. [View Abstract]
  37. Siegman-Igra Y, Schwartz D. Streptococcus bovis revisited: a clinical review of 81 bacteremic episodes paying special attention to emerging antibiotic resistance. Scand J Infect Dis. 2003. 35(2):90-3. [View Abstract]
  38. Terpenning MS, Buggy BP, Kauffman CA. Infective endocarditis: clinical features in young and elderly patients. Am J Med. 1987 Oct. 83(4):626-34. [View Abstract]
  39. Vilaichone RK, Mahachai V, Kullavanijaya P, Nunthapisud P. Spontaneous bacterial peritonitis caused by Streptococcus bovis: case series and review of the literature. Am J Gastroenterol. 2002 Jun. 97(6):1476-9. [View Abstract]
  40. Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA. 1995 Dec 6. 274(21):1706-13. [View Abstract]